Navigation Links
Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities, Trauma, and General Orthopaedics Market with Legato™ Bone Void Filler
Date:2/15/2011

RALEIGH, N.C., Feb. 15, 2011 /PRNewswire/ -- Pioneer Surgical Technology today announces the market launch of their new portfolio of biologic products, Legato, designed to be used in extremity, trauma, and general orthopaedic indications.

Legato Bone Void Filler will be showcased during the 2011 American Academy of Orthopaedic Surgeons (AAOS) convention in San Diego this week. Legato is a resorbable, collagen-based implant that acts as a scaffold for the in-growth of new bone and is designed to have broad appeal in extremity, trauma and general orthopaedic indications. In addition, Legato forms a cohesive and adhesive product easily shaped to defects while maximizing direct contact with host bone.

Regarding Pioneer's latest product introduction Mr. Shane Ray, General Manager – Biologics for Pioneer stated, "We are very pleased to expand our product offerings with Legato into the extremities, trauma and general orthopaedics market. Our goal has always been to establish highly effective products first in spine and now expanding into additional high growth markets such as extremities. We saw incredible sales growth in 2010 and are executing our 2011 growth plans to expand our product offerings within and outside the United States."

For more information regarding Pioneer's Biologics offerings including Legato, please visit the Pioneer Surgical website at www.pioneersurgical.com.

About Pioneer Surgical Technology, Inc.

Pioneer Surgical Technology, Inc. is a dynamic medical device firm founded in 1992. Pioneer's focus on innovation has resulted in over 120 U.S. and foreign patents, with numerous patents pending. The company has a comprehensive portfolio of orthopaedic, spine and biologic systems. Pioneer entered the orthobiologics market with two acquisitions in 2007. Our Orthopaedic, Spine, and Biologics divisions produce state of
'/>"/>

SOURCE Pioneer Surgical Technology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Pioneer® Surgical Expands Product Specialists to Support Growing Biologics Business
2. Pioneer® Surgical Technology, Inc. Announces Agreement to Acquire Exclusive Access to the Cequence™ Cervical Plate System From SpineSmith, LP
3. Pioneer® Surgical Technology, Inc. Announces Plans to Establish Manufacturing and Distribution Facility in Ireland
4. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain
6. Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes
7. New Non-Surgical Stem-Cell Procedure to Relieve Chronic Tendon Problems
8. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
9. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
10. Anesiva Commences Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Bunionectomy
11. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... PLAINS, N.Y. , July 23, 2014 /PRNewswire-USNewswire/ ... approval of idelalisib to treat patients with relapsed ... small lymphocytic lymphoma (SLL) is a significant advance ... Idelalisib, which goes by the trade name ... a protein that is highly expressed in many ...
(Date:7/23/2014)... July 23, 2014  Varian Medical Systems (NYSE: ... $1.02 per diluted share in the third quarter of ... about $0.06 per diluted share due to an approximately ... Varian,s existing equity investment in Augmenix, a privately-held company ... totaled $748 million for the third quarter of fiscal ...
(Date:7/23/2014)... Conn. , July 23, 2014 UBM ... – a new online community and information resource ... better manage and treat their patients with neurological ... coupled with an aging population, necessitates greater access to ... disorders.  Key statistics on neurological conditions include: ...
Breaking Medicine Technology:The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 10UBM Medica US Launches NeurologyTimes.com 2UBM Medica US Launches NeurologyTimes.com 3
... Rochester Medical Implants ( http://www.rmi.us.com ), a contract manufacturer ... it has relocated corporate offices and manufacturing operations to ... the location change, the company will change its name ... The new facility is a modern 33,000-square ...
... Calif., Oct. 17, 2011 ChemoCentryx, Inc., today ... trial for CCX168, an orally-administered small molecule for ... (AAV), a disease which can lead to renal ... receptor (C5aR), a potent pro-inflammatory mediator that is ...
Cached Medicine Technology:Rochester Medical Implants Relocates to New Facility in Noblesville, IN 2ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 2ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 3ChemoCentryx Initiates Phase II Clinical Trial for CCX168, a Novel Small Molecule C5aR Antagonist for the Treatment of Vasculitis 4
(Date:7/23/2014)... Lake Worth, FL (PRWEB) July 23, 2014 ... will take place Aug. 10-16, Millennium Treatment Group is ... Substance abuse has existed in society ever since man ... make wine. Substance abuse treatment has existed since shortly ... of recognizing a problem and then developing a way ...
(Date:7/23/2014)... July 23, 2014 A new study ... power morcellator ( http://www.injurybeacon.com/power-morcellator/ ) during minimally invasive ... throughout a woman’s body, Bernstein Liebhard LLP reports. The ... Journal of the American Medical Association, looked at 36,000 ... at 500 U.S. hospitals from 2006 to 2012. Ninety-nine ...
(Date:7/23/2014)... Alan Mozes HealthDay Reporter ... servicemen are more likely to have been exposed to some ... new survey suggests. The finding seems to apply solely ... that the finding could be a cause for concern, given ... and/or sexual abuse among the civilian population has been linked ...
(Date:7/23/2014)... YORK, NY, July 24, 2014) If past experience ... York State are about to get a lot more ... laws already on the books allowing NPs to provide ... to patient care and better relationships with physicians and ... a study from Columbia University School of Nursing, published ...
(Date:7/23/2014)... Randy Dotinga HealthDay Reporter ... A powerful drug combo may not be as effective ... on human cells suggests that one of the medications ... this study,s findings aren,t definitive, and there,s still hope ... and lumacaftor, according to the study,s senior author. ...
Breaking Medicine News(10 mins):Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 2Health News:Millennium Treatment Group Offers Tips on Choosing a Reputable Treatment Center 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Publication of New Study Confirming Potential for Uterine Morcellation to Spread Undetected Cancer 4Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 2Health News:Many U.S. Male Soldiers Had Troubled Childhoods, Study Finds 3Health News:New York law offers nurses more recognition, responsibility 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 2Health News:Cystic Fibrosis Drug Combo May Be Less Effective Than Hoped 3
... has earmarked $74 million to combat the bird flu threat ... was to announce the funding in Busan, Korea, where he ... ,International agencies, like the World Health Organization (WHO), would ... would go on a simulation exercise run by APEC to ...
... to the World Health Organization (WHO) experts, concerted ... complete eradication of the five neglected tropical diseases ... // years. , WHO has identified five ... leishmaniasis (kala azar), soil transmitted helminths (STH) and ...
... the national nursing shortage by producing more qualified nursing ... Robert W. Woodruff Foundation has awarded // $995,000 to ... support its new doctorate of nursing practice program, the ... ,Thanking the Atlanta-based Woodruff Foundation, a private organization, for ...
... by the Italian phrase 'malaria' — or 'bad air' — ... days, scientists know malaria is spread by mosquitos. // And ... the spread of a disease that kills 1 million people ... the situation is bad. The number of deaths are rising, ...
... hospital will begin performing open-heart surgeries on patients in ... new unit equipped with the // latest equipment including ... light, automatic operation bed and latest x-ray machines for ... superintendent, IGMC., ,The new unit will be launched ...
... movie may induce enough stress to interfere with your ... you sit down to watch a violent or // ... ability. ,David Beversdorf, a neurologist at the State ... and asked them to combine movie viewing with problem-solving ...
Cached Medicine News:Health News:Concerted Effort Imperative For Elimination Of Tropical Diseases: WHO 2Health News:Woodruff Foundation Grant To Support Doctorate Of Nursing Practice Program 2Health News:Malaria Vaccine May Be 10 Years Away 2Health News:Malaria Vaccine May Be 10 Years Away 3
... CO2 laser system used in neurophysiology for studying ... the amplitude and/or the duration of the stimulus ... the laser emission in an ongoing manner by ... this laser include the high repeatability of the ...
... advanced system for laser therapy available today. The ... fiber handpiece that allows to perform linear scanning ... 20% of the energy reflected by the skin. ... special gel which optimizes the optical coupling between ...
Smart Chill is a compact cooling system that provides intense localised skin cooling through a comfortable contact handpiece....
... Smart 1064 DW with the capability of ... nm) offering increased coagulative and ablative capacities.Smart 1064 ... between two different wavelengths: ordinary 1064 nm (with ... 1320 nm (with powers among 2 and 25 ...
Medicine Products: